Welcome to our dedicated page for Nymox Pharm SEC filings (Ticker: NYMXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a 250-page biotech filing packed with clinical data tables isn’t how most investors want to spend a morning—especially when Nymox Pharmaceutical’s future hinges on pivotal trial results for fexapotide triflutate. This page gathers every Nymox Pharmaceutical SEC filing the moment it hits EDGAR and explains what matters so you can skip straight to decisions.
Use Stock Titan’s AI-powered summaries to see, in plain English, what each form reveals: cash-burn trends in the latest Nymox Pharmaceutical quarterly earnings report 10-Q filing, new risk factors in the Nymox Pharmaceutical annual report 10-K simplified, or clinical milestones disclosed in an Nymox Pharmaceutical 8-K material events explained. Our platform highlights the pages discussing FDA interactions, trial endpoints, and financing covenants—so you’re never lost in technical jargon.
Need to monitor management’s moves? Real-time alerts surface every Nymox Pharmaceutical insider trading Form 4 transactions. Track Nymox Pharmaceutical executive stock transactions Form 4 alongside pipeline updates to gauge conviction. Planning to vote on proposals? The Nymox Pharmaceutical proxy statement executive compensation section clarifies how bonuses align with drug-approval milestones.
- All filings, all formats—10-K, 10-Q, 8-K, DEF 14A, S-3, and more—updated instantly
- AI context layers that make understanding Nymox Pharmaceutical SEC documents with AI effortless
- One-click Nymox Pharmaceutical Form 4 insider transactions real-time download for deeper analysis
Whether you’re comparing quarter-over-quarter R&D spend or looking for early signals before trial data drops, our AI delivers the Nymox Pharmaceutical earnings report filing analysis professionals rely on. No more wrestling with PDFs—get the clarity you need in minutes.
Nymox Pharmaceutical Corporation filed a 6-K stating that the U.S. District Court for the Central District of California granted the Company’s and Computershare Investor Services Inc.’s motion to dismiss Christopher Riley’s complaint and dismissed the case, with prejudice.
A dismissal “with prejudice” means the case is closed and cannot be refiled on the same claims. This removes an outstanding legal matter for Nymox without indicating any financial terms. The report was signed on November 7, 2025.
Nymox Pharmaceutical Corporation reported a final court outcome related to its 2023 litigation. The Supreme Court of the Bahamas issued its final order requiring Mr. Lanham, Mr. Riley, CRNSV, and other claimants to pay the Company $203,075.40. This award represents a percentage of expenses previously noted by the Company. The decision provides a defined cash recovery tied to the case and concludes this matter with a court-ordered payment to Nymox.
Nymox Pharmaceutical Corporation reported an insider share purchase. The company disclosed on Form 6-K that its CEO, Dr. Paul Averback, completed the purchase of 102,844 shares on October 20, 2025. The update records the transaction by the company’s chief executive and reflects an increase in his personal share ownership.
FAQ
What is the current stock price of Nymox Pharm (NYMXF)?
What is the market cap of Nymox Pharm (NYMXF)?
